These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 34985760)

  • 21. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.
    Gierach GL; Curtis RE; Pfeiffer RM; Mullooly M; Ntowe EA; Hoover RN; Nyante SJ; Feigelson HS; Glass AG; Berrington de Gonzalez A
    JAMA Oncol; 2017 Feb; 3(2):186-193. PubMed ID: 27711920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of ß-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study.
    Johannesdottir SA; Schmidt M; Phillips G; Glaser R; Yang EV; Blumenfeld M; Lemeshow S
    BMC Cancer; 2013 Feb; 13():85. PubMed ID: 23433478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. β-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis.
    Løfling LL; Støer NC; Sloan EK; Chang A; Gandini S; Ursin G; Botteri E
    Br J Cancer; 2022 Oct; 127(6):1086-1096. PubMed ID: 35725814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses.
    Vichapat V; Garmo H; Holmberg L; Fentiman IS; Tutt A; Gillett C; Lüchtenborg M
    Breast Cancer Res Treat; 2011 Nov; 130(2):609-18. PubMed ID: 21671018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beta blockers and angiotensin-converting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use.
    Holmes MD; Hankinson SE; Feskanich D; Chen WY
    Breast Cancer Res Treat; 2013 Jun; 139(2):507-13. PubMed ID: 23649190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016.
    Ramin C; Withrow DR; Davis Lynn BC; Gierach GL; Berrington de González A
    Breast Cancer Res; 2021 Feb; 23(1):24. PubMed ID: 33596988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors of developing contralateral breast cancer after first primary breast cancer treatment.
    Avatefi M; HadavandSiri F; Nazari SSH; Akbari ME
    Cancer Rep (Hoboken); 2024 Jan; 7(1):e1927. PubMed ID: 37919558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk.
    Kramer I; Hooning MJ; Mavaddat N; Hauptmann M; Keeman R; Steyerberg EW; Giardiello D; Antoniou AC; Pharoah PDP; Canisius S; Abu-Ful Z; Andrulis IL; Anton-Culver H; Aronson KJ; Augustinsson A; Becher H; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Bogdanova NV; Bojesen SE; Bolla MK; Bonanni B; Brauch H; Bremer M; Brucker SY; Burwinkel B; Castelao JE; Chan TL; Chang-Claude J; Chanock SJ; Chenevix-Trench G; Choi JY; Clarke CL; ; Collée JM; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Devilee P; Dörk T; Dos-Santos-Silva I; Dunning AM; Dwek M; Eccles DM; Evans DG; Fasching PA; Flyger H; Gago-Dominguez M; García-Closas M; García-Sáenz JA; Giles GG; Goldgar DE; González-Neira A; Haiman CA; Håkansson N; Hamann U; Hartman M; Heemskerk-Gerritsen BAM; Hollestelle A; Hopper JL; Hou MF; Howell A; ; ; Ito H; Jakimovska M; Jakubowska A; Janni W; John EM; Jung A; Kang D; Kets CM; Khusnutdinova E; Ko YD; Kristensen VN; Kurian AW; Kwong A; Lambrechts D; Le Marchand L; Li J; Lindblom A; Lubiński J; Mannermaa A; Manoochehri M; Margolin S; Matsuo K; Mavroudis D; Meindl A; Milne RL; Mulligan AM; Muranen TA; Neuhausen SL; Nevanlinna H; Newman WG; Olshan AF; Olson JE; Olsson H; Park-Simon TW; Peto J; Petridis C; Plaseska-Karanfilska D; Presneau N; Pylkäs K; Radice P; Rennert G; Romero A; Roylance R; Saloustros E; Sawyer EJ; Schmutzler RK; Schwentner L; Scott C; See MH; Shah M; Shen CY; Shu XO; Siesling S; Slager S; Sohn C; Southey MC; Spinelli JJ; Stone J; Tapper WJ; Tengström M; Teo SH; Terry MB; Tollenaar RAEM; Tomlinson I; Troester MA; Vachon CM; van Ongeval C; van Veen EM; Winqvist R; Wolk A; Zheng W; Ziogas A; Easton DF; Hall P; Schmidt MK
    Am J Hum Genet; 2020 Nov; 107(5):837-848. PubMed ID: 33022221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer.
    Hooning MJ; Aleman BM; Hauptmann M; Baaijens MH; Klijn JG; Noyon R; Stovall M; van Leeuwen FE
    J Clin Oncol; 2008 Dec; 26(34):5561-8. PubMed ID: 18854572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
    Su L; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2020 Jun; 146(12):3335-3342. PubMed ID: 32037537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for contralateral breast cancer in Chennai (Madras), India.
    Gajalakshmi CK; Shanta V; Hakama M
    Int J Epidemiol; 1998 Oct; 27(5):743-50. PubMed ID: 9839728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reproductive history and risk of second primary breast cancer: the WECARE study.
    Largent JA; Capanu M; Bernstein L; Langholz B; Mellemkaer L; Malone KE; Begg CB; Haile RW; Lynch CF; Anton-Culver H; Wolitzer A; Bernstein JL
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):906-11. PubMed ID: 17507614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Influence of Adjuvant Systemic Regimens on Contralateral Breast Cancer Risk and Receptor Subtype.
    Kramer I; Schaapveld M; Oldenburg HSA; Sonke GS; McCool D; van Leeuwen FE; Van de Vijver KK; Russell NS; Linn SC; Siesling S; Menke-van der Houven van Oordt CW; Schmidt MK
    J Natl Cancer Inst; 2019 Jul; 111(7):709-718. PubMed ID: 30698719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis.
    Caparica R; Bruzzone M; Agostinetto E; De Angelis C; Fêde Â; Ceppi M; de Azambuja E
    ESMO Open; 2021 Apr; 6(2):100066. PubMed ID: 33639601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study.
    Livingstone E; Hollestein LM; van Herk-Sukel MP; van de Poll-Franse L; Nijsten T; Schadendorf D; de Vries E
    Eur J Cancer; 2013 Dec; 49(18):3863-71. PubMed ID: 23942335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of metachronous contralateral breast cancer in patients with primary invasive lobular breast cancer: Results from a nationwide cohort.
    Akdeniz D; Kramer I; van Deurzen CHM; Heemskerk-Gerritsen BAM; Schaapveld M; Westenend PJ; Voogd AC; Jager A; Steyerberg EW; Sleijfer S; Schmidt MK; Hooning MJ
    Cancer Med; 2023 Feb; 12(3):3123-3133. PubMed ID: 36127572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen.
    Kwan ML; Shi JM; Habel LA; Song J; Chung JW; Avila CC; Schottinger JE; Cheetham TC; Fletcher SW; Haque R
    Breast Cancer Res Treat; 2016 Apr; 156(2):379-89. PubMed ID: 27002508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
    Drooger J; Akdeniz D; Pignol JP; Koppert LB; McCool D; Seynaeve CM; Hooning MJ; Jager A
    Breast Cancer Res Treat; 2015 Nov; 154(1):171-80. PubMed ID: 26467044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analytical approaches to minimizing immeasurable time bias in cohort studies.
    Oh IS; Baek YH; Jeong HE; Filion KB; Shin JY
    Int J Epidemiol; 2021 Jul; 50(3):987-999. PubMed ID: 33367629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Could treatments with beta-blockers be associated with a reduction in cancer risk?].
    Algazi M; Plu-Bureau G; Flahault A; Dondon MG; Lê MG
    Rev Epidemiol Sante Publique; 2004 Feb; 52(1):53-65. PubMed ID: 15107693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.